3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
17
Biliary Tract Neoplasms
13
Small Cell Lung Carcinoma
12
Cholangiocarcinoma
12
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Neoplasm Metastasis
5
Liver Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Carcinoma
4
Pancreatic Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
3
Gallbladder Neoplasms
3
Colorectal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Advanced Biliary Tract Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Vaccinia
1
SCLC, Limited Stage
1
Resectable Intrahepatic Cholangiocarcinoma
1
Interventions
durvalumab
1
Gemcitabine
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gallbladder Cancer Unresectable
×
durvalumab
×
Clear all
NCT06591650
2026-05-14
GCND
Fudan University
Phase 2
Recruiting
33 enrolled